Atalay, Selma, et al. “Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared With Standard Psoriasis Care: A Cost-Utility Analysis of the CONDOR Study”. Acta Dermato-Venereologica, vol. 100, no. 19, Dec. 2020, pp. 1-7, doi:10.2340/00015555-3692.